CEMIP and Familial prostate cancer: One study insisted, AMPK/GSK3β/β-catenin cascade triggered KIAA1199 over-expression may promote migration and invasion in anoikis-resistant prostate cancer cells by increasing PDK4-associated metabolic reprograming, which may provide a novel therapeutic target for the prostate cancer (Zhang et al., 2018).